'); //-->
Home
Help

Globe 100 Home
  | Index of coverage |

Top Ten
1. Teradyne Inc.
2. Analog Devices Inc.
3. LTX Corp.
4. EMC Corp.
5. Helix Tech. Corp.
6. ACT Manufacturing
7. Millipore Corp.
8. Talbots Inc.
9. Cytyc Corp.
10. FleetBoston

Year's Best
Company of year
Highest Market Value
Fastest Growth
Biggest Stock Gain
Comeback of the Year
Highest Sales

Contents
Overall performance
Banking
Biotech
Growth
  1. ACT Manuf.
  2. Provant Inc.
  3. Analog Devices
  4. Sapient Corp.
  5. Foilmark Inc.
Bulls and Bears
  Bulls
  1. J. Jill Group
  2. Inverness Medical
  3. Reebok Intl.
  4. Bostonfed Bancorp
  5. John Hancock
  Bears
  1. Aztec Tech.
  2. Engage Inc.
  3. CMGI Inc.
  4. Telaxis Comm.
  5. NaviSite Inc.
Employment
IPOs
Profitability
Sales


Charts
* The Globe 100
* Market value 100
* Sales 100
*
Return on equity 100
*
Growth 50
* Highest leveraged
* Top employers
* Most productive
* Industry summary
* Biggest profits
* Biggest losses
* The Bulls
* The Bears
* Top profit margins
* Debt-free companies
* Street's darlings
* Street's wallflowers
* 2000 Mass. IPOs
* Recoveries
* Nose Dives
All the charts for
this year's Globe 100


   | 2000 Globe 100 |

Sections Boston Globe Online: Page One Nation | World Metro | Region Business Sports Living | Arts Editorials


Search the Globe:

Today
Yesterday

The Boston Globe OnlineBoston.com Boston Globe Online / Business / 2001 Globe 100

Cytyc chief Patrick Sullivan
Patrick Sullivan, Cytyc's CEO, predicts 2001 will be as strong a year as 2000 -- thanks to the ThinPrep processor, above. (Globe File Photo)

9. CYTYC CORP.
Cancer test wins market share

5/22/2001

   
Top 10 Companies

1. Teradyne Inc.
2. Analog Devices Inc.
3. LTX Corp.
4. EMC Corp.
5. Helix Tech. Corp.
6. ACT Manufacturing
7. Millipore Corp.
8. Talbots Inc.
9. Cytyc Corp.
10. FleetBoston

Get the chart
The 2001 Globe 100
All the charts



hipping away at the Pap smear -- a test that reigned unrivaled for nearly 50 years and spared thousands of women the ravages of cervical cancer -- had been a slow and arduous process for Cytyc.

At the close of 1999, three years after the company's ThinPrep Pap test was approved by the Food and Drug Administration, Cytyc had gained only 19 percent of the market.

But 2000 proved to be a watershed year. By year's end, the ThinPrep had 36 percent of the market. Shares in the Boxborough company had doubled in value, to trade at about $20 each.

''You could really feel the momentum,'' said chief executive Patrick Sullivan.

Cytyc struck a deal with the nation's largest laboratory, responsible for processing about 10 million pap tests a year. It announced an agreement to couple the ThinPrep test with Roche Diagnostics' test for chlamydia.

Cytyc added more than 100 companies to the ranks of insurers that covered the ThinPrep test. It increased revenues by more than $60 million, reaching $142.1 million last year. And Sullivan said he expects 2001 to be an equally good year.

By the end of first-quarter 2001, ThinPrep had grabbed 41 percent of the market, increasing sales revenue by nearly 7 percent over the fourth quarter of last

year.

''There is no question that the ThinPrep Pap test is headed to being the standard of care,'' Sullivan said.

''We believe we'll be able to achieve 50 percent market share by the end of the year.''

NAOMI AOKI

   


Advertisment
Boston Globe Extranet
Extending our newspaper services to the web
© Copyright 2001 Globe Newspaper Company

Return to the home page
of The Globe Online

Click here for advertiser information